Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

·2 min read
Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

The clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. There are two reasons for Ziopharm's climb. First, it's a reaction to hitting its 52-week low as investors saw a potential bargain.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting